21,617 Shares in ANI Pharmaceuticals, Inc. $ANIP Bought by Artemis Investment Management LLP

Artemis Investment Management LLP acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 21,617 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,706,000.

A number of other large investors have also modified their holdings of the company. Illinois Municipal Retirement Fund raised its position in shares of ANI Pharmaceuticals by 1.7% in the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after acquiring an additional 145 shares during the period. Amalgamated Bank grew its position in shares of ANI Pharmaceuticals by 3.1% during the 3rd quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock valued at $464,000 after acquiring an additional 154 shares during the period. CANADA LIFE ASSURANCE Co increased its stake in shares of ANI Pharmaceuticals by 1.0% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 198 shares in the last quarter. Hantz Financial Services Inc. increased its stake in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in ANI Pharmaceuticals by 30.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock worth $86,000 after purchasing an additional 253 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insider Buying and Selling

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 3,162 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $71.64, for a total transaction of $226,525.68. Following the completion of the sale, the insider directly owned 91,309 shares in the company, valued at approximately $6,541,376.76. The trade was a 3.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $77.95, for a total value of $38,975.00. Following the transaction, the vice president directly owned 78,890 shares of the company’s stock, valued at $6,149,475.50. The trade was a 0.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 27,860 shares of company stock worth $2,111,581 in the last quarter. 8.10% of the stock is owned by insiders.

ANI Pharmaceuticals Stock Up 1.2%

ANIP stock opened at $80.39 on Friday. ANI Pharmaceuticals, Inc. has a 52 week low of $56.71 and a 52 week high of $99.50. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. The firm has a 50-day simple moving average of $76.36 and a 200-day simple moving average of $81.24. The stock has a market capitalization of $1.80 billion, a P/E ratio of 23.93 and a beta of 0.46.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Finally, Guggenheim upped their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.